MG
ATNM icon

Michael Gelband’s Actinium Pharmaceuticals ATNM Stock Holding History

Michael Gelband’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-57,934
Closed -$430K – 1687
2023
Q2 		$430K Sell
57,934
-2,343
-4% -$19.9K ﹤0.01% 1412
2023
Q1 		$570K Buy
60,277
+13,930
+30% +$147K ﹤0.01% 1302
2022
Q4 		$494K Buy
+46,347
New +$470K 0.01% 1178
2021
Q4 		– Sell
-17,800
Closed -$158K – 2149
2021
Q3 		$158K Buy
+17,800
New +$124K ﹤0.01% 1828
2021
Q1 		– Sell
-11,900
Closed -$93K – 2106
2020
Q4 		$93K Buy
+11,900
New +$129K ﹤0.01% 1836

Other funds holding ATNM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Michael Gelband's ATNM Position: Q3 2023 in Review

Michael Gelband sold out of Actinium Pharmaceuticals (ATNM) in Q3 2023, closing a stake of 57,934 shares — an estimated $430K sold.

Michael Gelband first reported a position in ATNM in Q4 2020 and held it in 5 quarters. The position peaked at $570K in Q1 2023. 58 funds tracked by Wall St. Rank hold ATNM as of Q3 2023.

  • Michael Gelband reported no remaining Actinium Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Michael Gelband sold 57,934 Actinium Pharmaceuticals shares in Q3 2023, an estimated $430K.
  • Michael Gelband first reported a position in Actinium Pharmaceuticals in Q4 2020 and held it in 5 quarters.
  • Michael Gelband's Actinium Pharmaceuticals position peaked at $570K in Q1 2023.
  • 58 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2023.

Based on ExodusPoint Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.